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Summary
Background Uncertainty in the risk of reproductive complications (pelvic inﬂ ammatory disease, ectopic pregnancy, 
and tubal factor infertility) following chlamydia infection and repeat infection hampers the design of evidence-based 
chlamydia control programmes. We estimate the association between diagnosed chlamydia and episodes of hospital 
health care (inpatient, outpatient, and emergency department) for a reproductive complication.
Methods We constructed and analysed a retrospective population-based cohort of women aged 15–44 years from 
administrative records in Denmark (1995–2012). We used a subset of the national Danish Chlamydia Study. The 
master dataset contains all residents of Denmark (including Greenland) who had a positive chlamydia test recorded 
by a public health microbiology laboratory from Jan 1, 1992, to Nov 2, 2011. Individuals were randomly matched (by 
age and sex) to four individuals drawn from the population register (Danish Civil Registration System) who did not 
have a positive chlamydia test during this interval. The outcomes in the study were hospital episodes of health-care 
(inpatient, outpatient, and emergency department) with a diagnosis of pelvic inﬂ ammatory disease, ectopic pregnancy, 
or tubal factor infertility.
Findings The 516 720 women (103 344 positive, 182 879 negative, 230 497 never-tested) had a mean follow-up of 
7·96 years. Compared with women with only negative tests, the risk of each complication was 30% higher in women 
with one or more positive tests (pelvic inﬂ ammatory disease, adjusted hazard ratio [AHR] 1·50 [95% CI 1·43–1·57]; 
ectopic pregnancy, AHR 1·31 [1·25–1·38]; tubal factor infertility, AHR 1·37 [1·24–1·52]) and 60% lower in women 
who were never-tested (pelvic inﬂ ammatory disease, AHR 0·33 [0·31–0·35]; ectopic pregnancy, AHR 0·42 [0·39–0·44]; 
tubal factor infertility AHR 0·29 [0·25–0·33]). A positive test had a minor absolute impact on health as the diﬀ erence 
in the lifetime incidence of complications was small between women who tested positive and those who tested 
negative (pelvic inﬂ ammatory disease, 0·6%; ectopic pregnancy, 0·2%; tubal factor infertility, 0·1%). Repeat infections 
increased the risk of pelvic inﬂ ammatory disease by a further 20% (AHR 1·20, 95% CI 1·11–1·31).
Interpretation A single diagnosed chlamydia infection increased the risk of all complications and a repeat diagnosed 
infection further increased the risk of pelvic inﬂ ammatory disease. Therefore, control programmes must prevent ﬁ rst 
and repeat infections to improve women’s reproductive health.
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Research Council Population Health Scientist Fellowship (G0902120). KT held an National Institute for Health 
Research Post-Doctoral Fellowship 2009-02-055.
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Introduction
Chlamydia trachomatis is the most common bacterial 
sexually transmitted infection in Europe.1 Many settings 
have introduced widespread chlamydia testing, which 
aims to reduce the incidence and prevalence of infection 
and the occurrence of reproductive com plications (pelvic 
inﬂ ammatory disease, ectopic preg nancy, and tubal 
factor infertility). However, there is uncertainty about 
the risk of complications following the pre dominantly 
asymptomatic infections that are identiﬁ ed by this 
approach.2–4
This uncertainty poses a challenge for health-care 
workers providing prognostic information to those 
oﬀ ered testing.5 It might compromise resource 
allocation decisions informed by estimates of the 
clinical and cost-eﬀ ectiveness of chlamydia control 
strategies from mathematical models that include 
estimates of this risk. Mathematical models commonly 
assume that 22% of women with an untreated chlamydia 
infection will progress to pelvic inﬂ ammatory disease6 
(assumed to be within 1 year) and of these, 8% will have 
an ectopic pregnancy, and 11% will develop infertility 
(not speciﬁ cally tubal factor infertility).7–12 These 
estimates are based largely on historical clinical studies. 
Population-based studies in settings with widespread 
chlamydia control suggest that the lifetime risk of pelvic 
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inﬂ ammatory disease in women with diagnosed (and 
presumably treated) chlamydia is less than 15% 
(Uppsala, Sweden: 5·6% [95% CI 4·7–6·7];5 
Sør-Trøndelag, Norway: 1·1% [0·8–1·4];13 Manitoba, 
Canada: 14·8%14). The lifetime risks of ectopic pregnancy 
and tubal factor infertility following pelvic inﬂ ammatory 
disease have not been reported using this study design, 
but the risks following chlamydia infection are low 
(ectopic pregnancy: Uppsala, 2·7% [95% CI 2·1–3·5];5 
Sør-Trøndelag, 0·8% [0·5–1·1];15 and infertility: Uppsala, 
6·7% [5·7–7·9]5).
There is a consistent 30–70% increased risk of pelvic 
inﬂ ammatory disease in women who test positive for 
chlamydia compared with women who test negative,5,13,14 
but there is no consensus on the equivalent risk of 
ectopic pregnancy (Uppsala, adjusted hazard ratio 
[AHR] 1·3 [95% CI 0·9–1·7];5 Sør-Trøndelag, AHR 1·1 
[1·0–1·1];15 Northern Jutland, Denmark, AHR 0·6 
[0·3–0·9]16), one estimate of the risk of infertility 
(Uppsala, AHR 1·31 [1·09–1·57]5), and no estimates of 
the risk of tubal factor infertility. Additionally, there is 
limited information on the risk of complications after 
repeat infection.
Consensus estimates of the risk of complications 
following chlamydia are necessary for clinical con-
sultations and chlamydia control policy decisions. Since 
the 1970s, Denmark has had a comprehensive electronic 
population register that can be linked to electronic 
health-care records and a well established chlamydia 
control programme with voluntary reporting of cases 
since 1984. We used a national cohort to improve 
estimates of the contemporary association between 
diagnosed chlamydia and pelvic inﬂ ammatory disease, 
ectopic pregnancy, and tubal factor infertility in women 
in Denmark, including never-tested women and after 
repeat diagnosed infections.
Research in context
Evidence before this study
We searched PubMed from Jan 1, 2008, to April 1, 2016, for 
studies that report the prospective risk of reproductive 
complications in low-risk women following chlamydia infection 
compared with a chlamydia-negative control group. We used 
the search term “Chlamydia trachomatis” combined with “pelvic 
inﬂ ammatory disease”, “salpingitis”, “endometritis”, 
“infertility”, or “ectopic pregnancy” and identiﬁ ed relevant 
studies restricted to the English language. We added these 
results to relevant studies identiﬁ ed by a 2010 systematic 
review and a study from the reference list of an included 
publication. The prospective risk of pelvic inﬂ ammatory disease 
following untreated genital chlamydia infection, treated 
infection, and a negative chlamydia test is presented in a single 
randomised controlled trial of 2529 women at low risk (9·5%, 
1·6%, and 1·3%, respectively). However, the sample size is too 
small to detect a diﬀ erence between groups in this secondary 
analysis. No prospective studies of the risk of ectopic pregnancy 
or infertility following untreated chlamydia infection were 
identiﬁ ed. Five retrospective cohort studies compare the 
lifetime risk of reproductive complications by chlamydia 
exposure in the general population. These studies show a 
30–70% increased risk of pelvic inﬂ ammatory disease in women 
who test positive for chlamydia compared with women who 
test negative. The three studies of ectopic pregnancy have not 
reached consensus and the single study of infertility uses data 
from before the widespread introduction of highly sensitive 
diagnostic tests. There is limited information on the role of 
repeat infection in reproductive complications.
Added value of this study
This cohort is considerably larger than the examples in the 
published literature and it is representative of the population of 
a country. It uses contemporary chlamydia test methods and 
the never-tested cohort has a straightforward deﬁ nition: 
women who do not have a chlamydia test during the cohort 
period. The size of the cohort has allowed us to report the 
contribution of a repeat diagnosed chlamydia infection to all 
three reproductive complications (pelvic inﬂ ammatory disease, 
ectopic pregnancy, and tubal factor infertility) for the ﬁ rst time 
in a single population.
Implications of all available evidence
Women with at least one diagnosed chlamydia infection have 
a 30% increased risk of pelvic inﬂ ammatory disease, ectopic 
pregnancy, and tubal factor infertility throughout their 
reproductive lifetime. The duration of the elevated risk of 
pelvic inﬂ ammatory disease is longer than the estimated 
1 year duration of untreated chlamydia infection. Therefore, in 
the case of pelvic inﬂ ammatory disease, chlamydia is likely to 
act as a proxy for other risk factors of adverse reproductive 
health (eg, sexual behaviour, repeat chlamydia infection) or a 
diagnostic bias. The absolute impact of diagnosed chlamydia 
infections on reproductive complications might be small. We 
observed a small diﬀ erence in the lifetime cumulative 
incidence of pelvic inﬂ ammatory disease, ectopic pregnancy, 
and tubal factor infertility between women who tested 
positive compared with women who tested negative. Women 
tested for chlamydia, who are negative, have an increased risk 
of complications compared with women who are 
never-tested. This ﬁ nding might indicate that widespread 
testing in Denmark is targeting the at-risk population. The risk 
of pelvic inﬂ ammatory disease following chlamydia infection 
is increased by a further 20% following a repeat diagnosed 
infection but we found no evidence that repeat infections 
further increase the risk of ectopic pregnancy or tubal factor 
infertility. Control interventions need to prevent ﬁ rst 
infections to reduce the lifetime risk of pelvic inﬂ ammatory 
disease, ectopic pregnancy, and tubal factor infertility, and 
repeat infections to further reduce the risk of pelvic 
inﬂ ammatory disease. 
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Methods
Dataset and data selection
We used a subset of the national Danish Chlamydia 
Study (appendix). The master dataset contains all 
residents of Denmark (including Greenland) who had a 
positive chlamydia test recorded by a public health 
microbiology laboratory from Jan 1, 1992, to Nov 2, 2011. 
Individuals were randomly matched (by age and sex) to 
four individuals drawn from the population register 
(Danish Civil Registration System [CRS register]) who 
did not have a positive chlamydia test during this interval. 
Controls could have had negative chlamydia tests. The 
unique ten-digit identiﬁ cation number for each 
individual in the cohort was used to extract demographic 
information (age, sex, postcode) from the CRS register; 
time interval of residence in Denmark from the CRS 
register; complete chlamydia test history from the public 
health microbiology laboratory data; and records of 
hospital health care (inpatient, outpatient, emergency 
department) from the Danish National Patient Registry 
(DNPR).
For this analysis, the master dataset was limited to 
women resident in Denmark (excluding Greenland) who 
entered the dataset after Jan 1, 1995, when aged 
15–44 years, and who were in a ﬁ ve-person set (one 
chlamydia-positive and four chlamydia-negative or never 
tested) who met the study chlamydia exposure 
deﬁ nitions. This start date was chosen because chlamydia 
notiﬁ cation became compulsory in Denmark in 1994 and 
in 1994–95 the DNPR changed from International Classi-
ﬁ cation of Disease (ICD)-9 to ICD-10 coding and added 
outpatient and emergency department presentations. 
Individuals with a positive chlamydia test entered the 
cohort on the date of their ﬁ rst positive test during the 
study period. Their four matched individuals were 
assigned the same entry date.
During the study period, chlamydia diagnostic methods 
varied between laboratories and the change from non-
nucleic acid methods to nucleic acid ampliﬁ cation tests 
(NAATs) occurred predominantly in 1999–2000. Records 
with an invalid or missing date, site, or result were 
removed along with tests not done on genital, rectal, or 
urinary samples. Where multiple eligible tests were 
recorded on the same date, positive results were retained 
in preference to negative results. Chlamydia tests were 
then restricted to one per 30-day period. The exposure in 
this study is chlamydia status and women were deﬁ ned 
as chlamydia-positive if their ﬁ rst test in the study cohort 
was positive, negative if they had at least one negative 
test, and no positive tests during the follow-up period or 
never-tested if they did not have a recorded test during 
follow-up.
Outcomes
The outcomes in this study were hospital episodes of 
health-care (inpatient, outpatient, and emergency depart-
ment) with a diagnosis of pelvic inﬂ ammatory disease 
(ICD-10 A18·1; A51·4; A52·7; A54·2; A56·1; N70-74·8), 
ectopic pregnancy (O00·00-00·9), or tubal factor 
infertility (N97·1). These data were added to the dataset. 
Follow-up continued until Oct 31, 2012. Women were 
censored on the ﬁ rst of the following events: emigration, 
death, 45th birthday, or their ﬁ rst hospital presentation 
with the relevant complication of interest.
Statistical analysis
We calculated the crude cumulative incidence of each 
complication by the end of follow-up (deﬁ ned as the 
number of women diagnosed with the complication by 
the end of follow-up divided by the number of women at 
baseline). We constructed Kaplan-Meier survival plots of 
time to each complication by chlamydia exposure status 
and used Cox proportional-hazards regression to explore 
the association between chlamydia exposure status and 
each complication separately, adjusted for age at cohort 
entry, and year of entry. Negative women formed the 
baseline group and time since entry was the time axis.
We then divided the follow-up period of positive 
women into the interval following their ﬁ rst positive test 
and the interval following their second positive test and 
estimated the association between this repeat diagnosed 
605 475 women in the Danish Chlamydia
  Study Master dataset
580 495 women born between 1965 and 
  1997 in the Danish Chlamydia Study 
554 266 women resident in Denmark, aged 
  15–44 years between 1995 and 2012 
516 720 women who met the chlamydia 
  exposure definition and were in a 
  five-person set (103 344 were positive, 
  182 879 were negative, and 
  230 497 never-tested)
  83 left the study before their entry date
               77 were older than 44 years at entry
                 6 were not residents of Denmark or 
                     Greenland
20 124 entered before 1995  
 382 were residents of Greenland
 5640 were younger than 15 years at entry
 7121 were labelled positive without a positive 
  test on date of entry
 60 were labelled negative with a positive 
  test during study
30 365 were not in a five-person set
69 847 negative women without a test during 
  the study were relabelled as never-tested
Figure 1: Formation of the study cohort from the Danish Chlamydia Study 
master dataset
See Online for appendix
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chlamydia infection and each complication separately. 
Statistical analysis was done using STATA SE 11.2 
(StataCorp LP, College Station, TX, USA).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
There were 516 720 women (103 344 [20%] positive, 
182 879 [35%] negative, and 230 497 [45%] never-tested) in 
the study cohort (ﬁ gure 1). The mean age at cohort entry 
was 22·4 years (SD 5·0; range 15·0–45·0), mean duration 
of follow-up was 8·0 years (median 7·2 years, range 1 day 
to 17·8 years, IQR 4·5–11·0), and total duration of follow-
up was 4 114 502 person-years.
The crude cumulative incidence of pelvic inﬂ ammatory 
disease in the study was 3·1% (95% CI 3·02–3·23; 3214 of 
103 344) in positive women, 2·5% (2·41–2·55; 4538 of 
182 879) in negative women, and 0·6% (0·57–0·63; 
1380 of 230 497) in never-tested women. The cumulative 
incidence of ectopic pregnancy was 2·2% (95% CI 
2·14–2·33; 2307 of 103 344) positive, 2·0% (1·97–2·10; 
3722 of 182 879) negative, and 0·6% (0·58–0·64; 1399 of 
230 497) never-tested. The cumulative incidence of tubal 
factor infertility was 0·6% (95% CI 0·54–0·63; 605 of 
103 344) positive, 0·5% (0·48–0·54; 930 of 182 879) 
negative, and 0·1% (0·09–0·12; 242 of 230 497) 
never-tested.
Women with an outcome on the date they entered the 
cohort were then excluded from the relevant analyses 
(pelvic inﬂ ammatory disease, n=459; ectopic pregnancy, 
n=52; tubal factor infertility, n=7). The rate of pelvic 
inﬂ ammatory disease was 403 per 100 000 person-years 
(95% CI 389–417) in positive women, 266 per 
100 000 person-years (258–274) in negative women, and 
89 (84–94) per 100 000 person-years in never-tested 
women. The rate of ectopic pregnancy was 284 per 
100 000 person years (95% CI 273–296) in positive 
women, 217 per 100 000 person-years (210–224) in 
negative women, and 90 per 100 000 person-years (86–95) 
in those never-tested. The rate of tubal factor infertility 
was 74 per 100 000 person-years (95% CI 68–80) in 
positive women, 54 per 100 000 person-years (50–57) in 
negative women, and 16 per 100 000 person-years (14–18) 
in never-tested women.
Kaplan-Meier survival curves are presented in ﬁ gure 2. 
The adjusted hazard of each outcome was 31–50% higher 
in women who tested positive compared with women 
who tested negative (pelvic inﬂ ammatory disease, AHR 
1·50 [95% CI 1·43–1·57]; ectopic pregnancy, AHR 1·31 
[1·25–1·38]; and tubal factor infertility, AHR 1·37 
[1·24–1·52]), and 58–71% lower in women who were 
never-tested compared with women who tested negative 
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Figure 2: Kaplan-Meier plots of time (years) to outcome by chlamydia exposure status
Pelvic inﬂ ammatory disease (A), ectopic pregnancy (B), and tubal factor infertility (C). 
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(pelvic inﬂ ammatory disease, AHR 0·33 [0·31–0·35]; 
ectopic pregnancy, AHR 0·42 [0·39–0·44]; and tubal 
factor infertility, AHR 0·29 [0·25–0·33]; table 1).
In the positive group, 23 011 (22·3%) women had one 
or more further positive chlamydia tests during follow-
up. The risk of pelvic inﬂ ammatory disease was 20% 
higher following a second diagnosed infection compared 
with a ﬁ rst diagnosed infection (AHR 1·20, 95% CI 
1·11–1·31) but the risk was unchanged for ectopic 
pregnancy (AHR 1·09, 0·99–1·20) and tubal factor 
infertility (AHR 1·06, 0·85–1·31; table 2).
Discussion
In this cohort of women from a contemporary setting 
with widespread chlamydia control who were tested for 
chlamydia, a positive chlamydia test increased the risk of 
pelvic inﬂ ammatory disease, ectopic pregnancy, and 
tubal factor infertility by at least 30%. This risk remained 
throughout 17 years of follow-up, which is considerably 
longer than the estimated 1 year duration of chlamydia 
infection.17 Therefore, the (treated) index infection might, 
in part, be a marker for other risk factors for pelvic 
inﬂ ammatory disease. The impact of the index positive 
chlamydia test on reproductive health was small in 
absolute terms because the diﬀ erence between the 
lifetime risks (cumulative incidence) of each outcome 
between women who tested positive and negative were 
small (0·1–0·6%). Finally, repeat diagnoses were a risk 
factor for pelvic inﬂ ammatory disease but not ectopic 
pregnancy or tubal factor infertility. These ﬁ ndings 
suggest that the optimal strategy for improving women’s 
long-term reproductive health is to provide interventions 
that prevent both ﬁ rst and repeat infections.
This nationally representative cohort of over 
500 000 women is an order of magnitude larger than pre-
viously published cohorts (Uppsala, 43 715;5 Sør-Trøndelag, 
24 947;13 North Jutland, 13 693;16 Manitoba, 72 88314). The 
size of the cohort together with the high volume of repeat 
testing allowed us to explore the risk of complications in 
never-tested women and following repeat diagnosed 
infections. There was complete ascertainment of 
chlamydia tests and hospital presentations for pelvic 
inﬂ ammatory disease, ectopic pregnancy, and tubal factor 
infertility in Denmark throughout the study.
In common with similar studies, there is an 
unquantiﬁ able misclassiﬁ cation bias in chlamydia and 
outcome status.5,13–15 We used chlamydia test records to 
assign lifetime chlamydia status but undiagnosed 
infections are likely to have occurred.5 Misclassiﬁ cation 
of outcome status is likely to be most marked for pelvic 
inﬂ ammatory disease in which the diagnostic criteria 
Pelvic inﬂ ammatory disease Ectopic pregnancy Tubal factor infertility
Crude HR (95% CI) Adjusted* HR (95% CI) p value Crude HR (95% CI) Adjusted* HR (95% CI) p value Crude HR (95% CI) Adjusted* HR (95% CI) p value
Chlamydia
Never 0·32 (0·30–0·34) 0·33 (0·31–0·35) <0·0001 0·43 (0·40–0·45) 0·42 (0·39–0·44) <0·0001 0·30 (0·26–0·35) 0·29 (0·25–0·33) <0·0001
Negative 1 1 1 1 1 1
Positive 1·48 (1·42–1·55) 1·50 (1·43–1·57) <0·0001 1·33 (1·26–1·40) 1·31 (1·25–1·38) <0·0001 1·41 (1·27–1·56) 1·37 (1·24–1·52) <0·0001
Age (years)
15–19 1 1 1 1 1 1
20–24 1·13 (1·07–1·18) 1·06 (1·01–1·12) 0·0132 1·37 (1·30–1·45) 1·36 (1·29–1·44) <0·0001 2·56 (2·21–2·97) 2·39 (2·07–2·77) <0·0001
25–29 1·18 (1·11–1·25) 1·17 (1·10–1·24) <0·0001 1·52 (1·42–1·62) 1·58 (1·48–1·69) <0·0001 4·69 (4·03–5·47) 4·65 (3·99–5·42) <0·0001
30–44 1·09 (1·00–1·18) 1·25 (1·15–1·35) <0·0001 1·06 (0·96–1·17) 1·19 (1·08–1·32) 0·0007 4·85 (4·05–5·80) 5·69 (4·76–6·81) <0·0001
Year
1995–2000 1 1 1 1 1 1
2001–07 0·79 (0·75–0·83) 0·83 (0·79–0·88) <0·0001 1·00 (0·95–1·06) 1·08 (1·02–1·14) 0·0071 0·68 (0·61–0·75) 0·74 (0·66–0·82) <0·0001
2008–12 0·62 (0·58–0·66) 0·79 (0·74–0·84) <0·0001 0·97 (0·90–1·05) 1·26 (1·16–1·36) <0·0001 0·43 (0·36–0·52) 0·62 (0·52–0·75) <0·0001
*Adjusted for chlamydia exposure, age at entry to cohort, and year of entry to cohort.
Table 1: Crude and adjusted hazard ratios (HRs) of pelvic inﬂ ammatory disease, ectopic pregnancy, and tubal factor infertility by chlamydia exposure status
Pelvic inﬂ ammatory disease Ectopic pregnancy Tubal factor infertility
Adjusted* HR
(95% CI)
p value Adjusted* HR
(95% CI)
p value Adjusted* HR
(95% CI)
p value
Diagnosed infections
1 1 1 1
≥2 1·20 (1·11–1·31) <0·0001 1·09 (0·99–1·20) 0·0918 1·06 (0·85–1·31) 0·6115
Age (years)
15–19 1 1 1
20–24 0·81 (0·74–0·87) <0·0001 1·07 (0·97–1·18) 0·1725 2·24 (1·75–2·88) <0·0001
25–29 0·78 (0·70–0·87) <0·0001 1·18 (1·05–1·33) 0·0064 3·97 (3·05–5·17) <0·0001
30–44 0·99 (0·86–1·13) 0·8699 0·98 (0·83–1·17) 0·8315 5·82 (4·34–7·80) <0·0001
Year
1995–2000 1 1 1
2001–07 0·75 (0·69–0·81) <0·0001 1·05 (0·95–1·16) 0·3096 0·67 (0·56–0·81) <0·0001
2008–12 0·59 (0·53–0·66) <0·0001 1·06 (0·92–1·21) 0·4171 0·54 (0·40–0·73) <0·0001
*Adjusted for chlamydia exposure, age at entry to cohort, and year of entry to cohort.
Table 2: Adjusted hazard ratios (HRs) of pelvic inﬂ ammatory disease, ectopic pregnancy, and tubal factor 
infertility following a repeat chlamydia diagnosis 
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are non-speciﬁ c, there is no gold-standard non-invasive 
diagnostic test,18 and a diagnostic bias towards pelvic 
inﬂ ammatory disease in women with a past history of 
chlamydia.2 This proposed diagnostic bias would 
increase the association between chlamydia and pelvic 
inﬂ am matory disease if it aﬀ ected hospital episodes of 
health care and could contribute to the observed 
increased risk of pelvic inﬂ ammatory disease after a 
repeat diagnosed infection.
Primary care data were not available in this study. This 
incomplete ascertainment of complications is likely to 
have had the greatest impact on the analysis of pelvic 
inﬂ ammatory disease where there has been a steady 
increase in management in the outpatient or community 
setting.19,20 If there is no association between the cause of 
pelvic inﬂ ammatory disease and clinical presentation 
then the absence of cases managed solely in primary care 
will reduce the cumulative incidence but not change the 
relative risk across exposure groups. However, pelvic 
inﬂ ammatory disease due to chlamydia might have a 
milder clinical presentation than other causes.21 If pelvic 
inﬂ ammatory disease in chlamydia-negative women is 
more likely to be recorded in the DNPR this would 
underestimate the association between chlamydia and 
pelvic inﬂ ammatory disease. This is unlikely to be 
relevant in this study because Neisseria gonorrhoea, a 
major cause of severe pelvic inﬂ ammatory disease, is 
rare in Denmark (80% of the 490 patients with 
gonorrhoea in Denmark in 2011 were men).22
There is uncertainty in the validity of our ICD 
deﬁ nitions to accurately represent a relevant diagnosis in 
the clinical record. This uncertainty has been well 
documented for pelvic inﬂ ammatory disease23–25 but 
might be less pronounced for ectopic pregnancy and 
tubal factor infertility because they have more speciﬁ c 
diagnostic criteria. To improve validity, we restricted the 
cohort to women who entered after 1995 when ICD-10 
coding was introduced, and emergency department and 
outpatient data were added to the DNPR. This period 
also coincided with the shift from voluntary to com-
pulsory notiﬁ cation of chlamydia in 1994.
The structure of the study cohort was a trade-oﬀ 
between the completeness of exposure and outcome 
measures and the duration of follow-up. By starting on 
Jan 1, 1995, it was possible for the youngest women (at 
study entry) to reach the mean age of ﬁ rst childbirth in 
Denmark by the end of follow-up, although they did not 
reach the end of their reproductive lifetime. Exposure 
and outcome ascertainment was also comprehensive. 
The validity of a chlamydia test result will have changed 
following the introduction of NAATs in 1999–2000. 
NAATs have a high sensitivity compared with enzyme 
immunoassays and direct immuno ﬂ uorescence tests. 
However, the pathogenicity of detected infections might 
vary with test type and be lowest for NAATs. In support of 
this, infection resolution rates have been shown to be 
higher in people diagnosed by the use of NAATs 
compared with enzyme immun oassay or culture.26 
Therefore, the association between diagnosed infections 
and reproductive complications might alter over time as 
the predominant diagnostic test changes.
To control for this, we adjusted the analysis for year of 
entry to the cohort. We were unable to control for many 
potential confounders, including sexual behaviour, 
reproductive intent, and sexual network, due to the 
absence of suitable data. We chose to include all women 
in our analysis of ectopic pregnancy rather than 
restricting the cohort to women who had a recorded 
pregnancy. This might explain the lower AHR of ectopic 
pregnancy following diagnosed chlamydia observed in 
women aged 30–44 years at cohort entry compared with 
women aged 25–29 years. Speciﬁ cally, the rate of 
conception is likely to be lower in the older age group, 
and therefore if the true risk of ectopic pregnancy as the 
outcome of pregnancy is the same across age groups, the 
AHR would be lower in older women if the incidence of 
pregnancy was lower.
We used the Cox proportional hazards model in this 
study. This standard non-parametric method for 
modelling time-to-event data was used in the ﬁ ve 
comparator cohort studies.5,13–16 The assumption of 
proportional hazards was violated in our analysis but this 
was not unexpected given the structure of our dataset: 
events at baseline are likely to become poorer predictors 
of events that occur after increasing time intervals. We 
explored several alternative methods for analysing the 
data;27 however, we felt it was appropriate to report the 
ﬁ ndings of this Cox regression to enable direct 
comparison of the risk of complications in Denmark to 
other settings.
Our ﬁ ndings of an increased risk of pelvic inﬂ ammatory 
disease in chlamydia-positive women compared with 
chlamydia-negative women (AHR 1·50, 95% CI 
1·43–1·57) is consistent with AHR estimates from 
comparable population-based cohorts (Uppsala, 1·27 
[1·04–1·55];5 Sør-Trøndelag, 1·69 [1·21–2·37];13 and 
Manitoba, 1·55 [1·43–1·70])14 despite diﬀ erences in 
cohort structure, deﬁ nition of chlamydia exposure, and 
pelvic inﬂ ammatory disease ascertainment. This in-
creased risk is present throughout the reproductive 
lifetime and therefore the index chlamydia test is likely, 
at least in part, to be a surrogate for other risk factors for 
pelvic inﬂ ammatory disease, most likely undiagnosed 
sexually transmitted infections, including repeat 
chlamydia infections, which might be mediated through 
sexual or health-care seeking behaviour.
There is conﬂ icting evidence in the literature about the 
relation between a chlamydia diagnosis and ectopic 
pregnancy. We found that a positive test increased the 
risk of ectopic pregnancy (as the outcome of any 
pregnancy) by 31% (AHR 1·31, 95% CI 1·25–1·38) 
compared with women with a negative test. This ﬁ nding 
is consistent with the other study that included all 
women (Uppsala, AHR 1·26, 0·94–1·67).5 Two further 
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studies limited their analysis to the ﬁ rst pregnancy in 
women with a pregnancy during follow-up and found a 
45% decreased risk (Northern Jutland, AHR 0·55, 
95% CI 0·31–3·59)16 and 7% increased risk 
(Sør-Trøndelag, 1·07, 1·01–1·12).15
Chlamydia is thought to be a risk factor for tubal factor 
infertility rather than infertility more widely, and this is 
the only retrospective cohort study that has restricted the 
deﬁ nition of infertility to tubal factor infertility. As tubal 
factor infertility is a subset of the overall infertility 
diagnoses it is expected that the cumulative incidence of 
tubal factor infertility would be lower than the cumulative 
incidence of infertility and we report a ten times lower 
cumulative incidence of tubal factor infertility compared 
with that of infertility in Uppsala. It is diﬃ  cult to explain 
the similar increased HR for tubal factor infertility 
and infertility in chlamydia-positive compared with 
chlamydia-negative women in the two cohorts (Denmark, 
AHR 1·37 [95% CI 1·24–1·52]; Uppsala, 1·31 [1·09–1·57]).5
In this cohort, women with a diagnosed (and presumably 
treated) chlamydia infection had a low absolute risk of 
complications (cumulative incidence in positive women: 
pelvic inﬂ ammatory disease, 3·1%; ectopic pregnancy, 
2·2%; tubal factor infertility, 0·6%) that was only slightly 
higher than that observed in women with a negative test 
(0·1–0·6% higher in positive than negative women). This 
information might provide reassurance to women who 
have a chlamydia test. However, this diﬀ erence in risk is 
equivalent to 9·1–19·3% of the recorded complications in 
positive women. Therefore, chlamydia control inter-
ventions that prevent ﬁ rst infections and retain women in 
the lifetime-negative cohort could have an important eﬀ ect 
on reproductive health.
In Denmark, widespread chlamydia testing appears to 
have been eﬀ ectively targeted to women at risk of 
reproductive complications because the observed risks in 
never-tested women were extremely low. Nonetheless, 
some never-tested women did experience complications 
and might have missed out on appropriate health care. 
We observed a much lower risk of all complications in 
this group (compared with negative women) than the 
Uppsala study (eg, pelvic inﬂ ammatory disease: AHR 
0·32 [95% CI 0·30–0·34] in Denmark and 0·72 
[0·63–0·82] in Uppsala.)5 This ﬁ nding might reﬂ ect 
diﬀ erences in the deﬁ nition of the never-tested cohorts 
(lifetime never-tested in Demark compared with the 
interval before the ﬁ rst test in Uppsala) or an increased 
uptake of testing in Denmark due to the more recent 
time period.
This study adds substantially to the evidence that a 
repeat diagnosis of chlamydia further increases the risk 
of pelvic inﬂ ammatory disease14,28 and we observed a very 
similar increased risk following a second diagnosed 
infection (11–31%) to the cohort in Manitoba (13–23%).14 
Unlike in Sør-Trøndelag we did not ﬁ nd that a repeat 
diagnosed infection was a risk factor for ectopic 
pregnancy but this could reﬂ ect diﬀ erences in study 
deﬁ nitions (including cohort and ectopic pregnancy) 
rather than biological diﬀ erences.15 Our observation that 
a repeat diagnosed infection was only a risk factor for 
pelvic inﬂ ammatory disease could be because each 
episode of chlamydia carries a discrete risk of pelvic 
inﬂ ammatory disease, whereas damage to the oviducts, 
suﬃ  cient to cause ectopic pregnancy and tubal factor 
infertility, might occur before the median duration of a 
ﬁ rst infection.
A single diagnosed chlamydia infection increases the 
risk of all reproductive complications in women and a 
repeat diagnosis further increases the risk of pelvic 
inﬂ ammatory disease. To improve women’s long-term 
reproductive health and wellbeing, chlamydia control 
programmes must be designed to prevent both ﬁ rst and 
repeat infections. To inform the design of widespread 
chlamydia control interventions, more information is 
required on the relative contribution of chlamydia control 
activity (ie, interventions that reduce the incidence 
of untreated infections), change in the incidence of 
gonorrhoea, and change in the pathogenicity of diagnosed 
chlamydia infections after the introduction of NAATs29 
on the risk of reproductive complications.
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